Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

55.43 +1.03 (+1.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,322,134
Open 54.89
Bid (Size) 51.51 (3)
Ask (Size) 55.57 (1)
Prev. Close 54.40
Today's Range 54.81 - 55.88
52wk Range 46.12 - 58.10
Shares Outstanding 1,250,690,553
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support. 
Via Benzinga
FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule
The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc. 
Via Benzinga

Performance

YTD
+9.35%
+9.35%
1 Month
+1.63%
+1.63%
3 Month
+6.43%
+6.43%
6 Month
+10.93%
+10.93%
1 Year
+3.28%
+3.28%

More News

Read More
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Via Benzinga
Why Kymera Therapeutics Shares Are Falling Today
Via Benzinga
Dupixent, Consumer Healthcare Lifts Sanofi's Q1 Earnings, Backs FY22 Guidance
Via Benzinga
Sanofi Scores A Big Beat As Dupixent Snags The Spotlight, Again
Via Investor's Business Daily
7 Penny Stocks With 10x Potential This Year
Via InvestorPlace
Sanofi To Pay €400K As Compensation For Epilepsy Drug-Related Side Effects
Via Benzinga
Sanofi Says Sarclisa Shows 'Unprecedented Median Progression-Free Survival' In Multiple Myeloma Patients
Via Benzinga
Eli Lilly, Novo Nordisk, Sanofi Accused Of Artificially Raising Insulin Prices
Via Benzinga
Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now
Via Investor's Business Daily
Psychedelic Medicine: The New Frontier In Healthcare, The Big Opportunity In Biopharma
Via Talk Markets
Is Dario (DRIO) Health Eating Teladoc's (TDOC) Lunch? Q1 Earnings on Tap Thursday After Meeting with Sanofi (SNY)
Via Benzinga
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Via Benzinga
Sanofi-AstraZeneca Say New Nirsevimab Data Reinforce Efficacy Against RSV
Via Benzinga
Heart Failure Treatment Offers Hope to Diabetics
Via FinancialNewsMedia
7 Biotech Stocks With Key Catalysts for May
Via InvestorPlace
Stock Market Volatile; Apple, Facebook, Amazon Are Key Earnings, Tesla CEO Elon Musk Buys Twitter: Weekly Review
Via Investor's Business Daily
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Via Benzinga
Earnings Scheduled For April 28, 2022
Via Benzinga
Microsoft Gives Glimpse Of Xbox Cloud Gaming Numbers
Via Benzinga
This Digital Healthcare Company Is Reporting Multiple New Contracts That It Hopes Might Take It To New Levels
Via Benzinga
Psyched: Big Pharma's Sanofi Enters Psychedelics Space, DNA From 80 Psilocybe Mushrooms Published Online, Maine Psychedelics Bill Shelved
Via Benzinga
Big Pharma's Sanofi Enters Licencing Agreement With Private Psychedelics Company Terran
Via Benzinga
Public-health Authorities in US, UK, Probe Mysterious Cases Of Severe Hepatitis In Young Kids: WSJ
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.